| Why Nucor's Stock Dip Could Be a Golden Opportunity in Disguise |
Nucor (NYSE: NUE) isn't just another steelmaker churning out metal for skyscrapers and rebar. It's a powerhouse that has weathered economic storms, steel cycles, and shifting energy costs, all while steadily raising its dividend for over the past half century. Yet, despite that remarkable consistency, investors seems to be snoozing on Nucor right now so is it time to buy? Get the full details here |
Ivy Content you May Have Missed
|
Is the Market Flashing Red? |
Warren Buffett isn't a market timer. Never has been, never will be. Instead, he's a value hawk, someone who circles the skies looking for bargains and only swoops in when the numbers justify it. In his 1994 letter to shareholders, Buffett put it plainly: "We try to price, rather than time, purchases." That simple principle explains why he often appears to be doing… well, nothing. When prices are irrationally high, Buffett is perfectly content sitting on a mountain of cash. Get the full details here |
Jack's Fintech Giant Just Quadrupled Profits |
The stock market has a way of turning heroes into villains overnight, and Block is a perfect case study. Just a few years ago, it was one of the hottest names on Wall Street, riding high on the wave of digital adoption. Fast forward to today, and the stock is trading nearly 80% below its all-time highs. For many investors, that kind of collapse leaves a scar. But for others, it leaves an opening. Get the full details here |
| Sponsored | | The Pentagon Backs "War-Proof" Energy | | With missiles flying (again) in the Middle East, this new Pentagon-backed, "war-proof" form of energy may prove more important than ever. It's kind not oil, nuclear, or solar. And it can't be hacked, bombed, or seized by terrorists. Even better, there's enough of it under U.S. soil to power the country for thousands of years. Billionaires are already invested. And we name the one company at the center of it all in this brand new video. Watch it here. | | Privacy Policy/Disclosures |
|
4% Dividend + 12x Earnings = Blockbuster in the Making |
Merck has long been a pillar of stability in the pharmaceutical world, thanks in large part to the staggering success of its cancer drug Keytruda. But behind that success lies a quietly growing concern of what happens when the patents expire? In a move that could reshape its future, Merck just announced a $10 billion acquisition of Verona Pharma. Get the full details here |
|
 |
|
| | Advertising Disclosure: This email may contain paid advertisements. Summa Money publishes 4 newsletters with various areas of focus. The Ivy is delivered 3x per week with a focus on investments that could generate passive income. The Burst is delivered 2x per week with a focus on growth stocks. The Spotlight is delivered 1x per week with a focus on high potential stocks and economic insights. The Daily is an occasional newsletter with a focus on the best investing stories and news from around the world. We hope you enjoy them all, but feel free to unsubscribe from the content you do not want to receive. If you do not wish to receive this email, then we apologize for the inconvenience. You can immediately discontinue receiving this email by clicking the unsubscribe link at the bottom of this email. If you have any questions, please send an email with your questions to support@summamoney.com. Nothing in this email should be considered personalized financial advice. We strongly urge you to read our full disclaimer here. If you can't see this message, view it in your browser. You are receiving this e-mail at edwardlorilla1986.paxforex@blogger.com as a part of your free subscription to the Ivy Newsletter. To read our privacy policy follow this link. or To unsubscribe by mail, write us at: Summa Money | 2319 N Andrews Ave. Fort Lauderdale, FL 33311 Website: Summa Money Nothing in this email should be considered personalized financial advice. Staff members at Summa Money are not qualified to answer your investing-related questions as they are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Copyright 2024 Summa Money. All rights reserved. Advertise With Us |
|
|
In order to unsubscribe from this mailing list, please click
here 
Post a Comment
0Comments